These Analysts Increase Their Forecasts On Inspire Medical After Strong Q3 Results

Inspire Medical Systems, Inc. (NYSE:INSP) reported upbeat earnings for the third quarter on Monday.

The company posted quarterly earnings of 14 cents per share which beat the analyst consensus estimate of 9 cents per share. The company reported quarterly sales of $206.695 million which beat the analyst consensus estimate of $204.304 million.

Inspire Medical Systems narrowed its FY2026 adjusted EPS guidance from $1.05-$1.45 to $1.20-$1.40 and also narrowed sales guidance from $835.000 million-$875.000 million to $850.000 million-$860.000 million.

“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic. We will stay disciplined in our education initiatives and focused on executing our strategic priorities as we finish out 2026 and plan for a return to growth in 2027,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.

Inspire Medical shares gained 0.4% to $67.50 in pre-market trading.

These analysts made changes to their price targets on Inspire Medical following earnings announcement.

• Baird analyst Mike Polark maintained Inspire Medical Systems with a Neutral and raised the price target from $73 to $77.
• Piper Sandler analyst Adam Maeder maintained the stock with a Neutral and raised the price target from $60 to $70.

Considering buying INSP stock? Here’s what analysts think:

Photo via Shutterstock